Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies
Background:
The World Health Organization recommends the screening of all people living with HIV for tuberculosis (TB) disease, followed by TB treatment, or isoniazid preventive therapy (IPT) when TB is excluded. However, the difficulty of reliably excluding TB disease has severely limited TB screening and IPT uptake in resource-limited settings. We conducted an individual participant data meta-analysis of primary studies, aiming to identify a sensitive TB screening rule.
Methods and Findings:
We identified 12 studies that had systematically collected sputum specimens regardless of signs or symptoms, at least one mycobacterial culture, clinical symptoms, and HIV and TB disease status. Bivariate random-effects meta-analysis and the hierarchical summary relative operating characteristic curves were used to evaluate the screening performance of all combinations of variables of interest. TB disease was diagnosed in 557 (5.8%) of 9,626 people living with HIV. The primary analysis included 8,148 people living with HIV who could be evaluated on five symptoms from nine of the 12 studies. The median age was 34 years. The best performing rule was the presence of any one of: current cough (any duration), fever, night sweats, or weight loss. The overall sensitivity of this rule was 78.9% (95% confidence interval [CI] 58.3%–90.9%) and specificity was 49.6% (95% CI 29.2%–70.1%). Its sensitivity increased to 90.1% (95% CI 76.3%–96.2%) among participants selected from clinical settings and to 88.0% (95% CI 76.1%–94.4%) among those who were not previously screened for TB. Negative predictive value was 97.7% (95% CI 97.4%–98.0%) and 90.0% (95% CI 88.6%–91.3%) at 5% and 20% prevalence of TB among people living with HIV, respectively. Abnormal chest radiographic findings increased the sensitivity of the rule by 11.7% (90.6% versus 78.9%) with a reduction of specificity by 10.7% (49.6% versus 38.9%).
Conclusions:
Absence of all of current cough, fever, night sweats, and weight loss can identify a subset of people living with HIV who have a very low probability of having TB disease. A simplified screening rule using any one of these symptoms can be used in resource-constrained settings to identify people living with HIV in need of further diagnostic assessment for TB. Use of this algorithm should result in earlier TB diagnosis and treatment, and should allow for substantial scale-up of IPT.
: Please see later in the article for the Editors' Summary
Vyšlo v časopise:
Development of a Standardized Screening Rule for Tuberculosis in People Living with HIV in Resource-Constrained Settings: Individual Participant Data Meta-analysis of Observational Studies. PLoS Med 8(1): e32767. doi:10.1371/journal.pmed.1000391
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1000391
Souhrn
Background:
The World Health Organization recommends the screening of all people living with HIV for tuberculosis (TB) disease, followed by TB treatment, or isoniazid preventive therapy (IPT) when TB is excluded. However, the difficulty of reliably excluding TB disease has severely limited TB screening and IPT uptake in resource-limited settings. We conducted an individual participant data meta-analysis of primary studies, aiming to identify a sensitive TB screening rule.
Methods and Findings:
We identified 12 studies that had systematically collected sputum specimens regardless of signs or symptoms, at least one mycobacterial culture, clinical symptoms, and HIV and TB disease status. Bivariate random-effects meta-analysis and the hierarchical summary relative operating characteristic curves were used to evaluate the screening performance of all combinations of variables of interest. TB disease was diagnosed in 557 (5.8%) of 9,626 people living with HIV. The primary analysis included 8,148 people living with HIV who could be evaluated on five symptoms from nine of the 12 studies. The median age was 34 years. The best performing rule was the presence of any one of: current cough (any duration), fever, night sweats, or weight loss. The overall sensitivity of this rule was 78.9% (95% confidence interval [CI] 58.3%–90.9%) and specificity was 49.6% (95% CI 29.2%–70.1%). Its sensitivity increased to 90.1% (95% CI 76.3%–96.2%) among participants selected from clinical settings and to 88.0% (95% CI 76.1%–94.4%) among those who were not previously screened for TB. Negative predictive value was 97.7% (95% CI 97.4%–98.0%) and 90.0% (95% CI 88.6%–91.3%) at 5% and 20% prevalence of TB among people living with HIV, respectively. Abnormal chest radiographic findings increased the sensitivity of the rule by 11.7% (90.6% versus 78.9%) with a reduction of specificity by 10.7% (49.6% versus 38.9%).
Conclusions:
Absence of all of current cough, fever, night sweats, and weight loss can identify a subset of people living with HIV who have a very low probability of having TB disease. A simplified screening rule using any one of these symptoms can be used in resource-constrained settings to identify people living with HIV in need of further diagnostic assessment for TB. Use of this algorithm should result in earlier TB diagnosis and treatment, and should allow for substantial scale-up of IPT.
: Please see later in the article for the Editors' Summary
Zdroje
1. GetahunH
GunnebergC
GranichR
NunnP
2010 HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis 50 S201 207
2. SonnenbergP
GlynnJR
FieldingK
MurrayJ
Godfrey-FaussettP
2005 How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 191 150 158
3. HavlirDV
GetahunH
SanneI
NunnP
2008 Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 300 423 430
4. MukadiYD
WiktorSZ
CoulibalyIM
CoulibalyD
MbengueA
1997 Impact of HIV infection on the development, clinical presentation, and outcome of tuberculosis among children in Abidjan, Cote d'Ivoire. Aids 11 1151 1158
5. ManosuthiW
ChottanapandS
ThongyenS
ChaovavanichA
SungkanuparphS
2006 Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43 42 46
6. LawnSD
MyerL
OrrellC
BekkerLG
WoodR
2005 Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. Aids 19 2141 2148
7. GandhiNR
MollA
SturmAW
PawinskiR
GovenderT
2006 Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368 1575 1580
8. WellsCD
CegielskiJP
NelsonLJ
LasersonKF
HoltzTH
2007 HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 Suppl 1 S86 107
9. BadriM
WilsonD
WoodR
2002 Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 359 2059 2064
10. MirandaA
MorganM
JamalL
LasersonK
BarreiraD
2007 Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS ONE 2 e826 doi:10.1371/journal.pone.0000826
11. LawnSD
MyerL
BekkerLG
WoodR
2006 Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. Aids 20 1605 1612
12. BurgessAL
FitzgeraldDW
SevereP
JosephP
NoelE
2001 Integration of tuberculosis screening at an HIV voluntary counselling and testing centre in Haiti. Aids 15 1875 1879
13. AkoloC
AdetifaI
ShepperdS
VolminkJ
2010 Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev CD000171
14. WHO 2004 Interim policy on collaborative TB/HIV activities, World Health Organization. Geneva: WHO. WHO/HTM/TB/2004.330 WHO/HTM/HIV/2004.1. 2004
15. WHO 2010 Global tuberculosis control report: World Health Organization. Geneva: WHO. WHO/HTM/TB/ 2010.7
16. ReidMJ
ShahNS
2009 Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 9 173 184
17. GetahunH
HarringtonM
O'BrienR
NunnP
2007 Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369 2042 2049
18. AylesH
SchaapA
NotaA
SismanidisC
TembweR
2009 Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS One 4 e5602 doi:10.1371/journal.pone.0005602
19. CorbettEL
ZezaiA
CheungYB
BandasonT
DauyaE
2010 Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ 88 13 21
20. CainKP
McCarthyKD
HeiligCM
MonkongdeeP
TasaneeyapanT
2010 An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 362 707 716
21. DayJH
CharalambousS
FieldingKL
HayesRJ
ChurchyardGJ
2006 Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 10 523 529
22. CorbettEL
BandasonT
CheungYB
MunyatiS
Godfrey-FaussettP
2007 Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 4 e22 doi:10.1371/journal.pmed.0040022
23. LewisJJ
CharalambousS
DayJH
FieldingKL
GrantAD
2009 HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 180 1271 1278
24. ShahS
DemissieM
LambertL
AhmedJ
LeulsegedS
2009 Intensified tuberculosis case finding among HIV-Infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J Acquir Immune Defic Syndr 50 537 545
25. KimerlingME
SchuchterJ
ChantholE
KunthyT
StuerF
2002 Prevalence of pulmonary tuberculosis among HIV-infected persons in a home care program in Phnom Penh, Cambodia. Int J Tuberc Lung Dis 6 988 994
26. LawnS
EdwardsD
KranzerK
VogtM
BekkerL
2009 Urine lipoarabinomannan assay for tuberculosis screening prior to antiretroviral therapy: diagnostic yield and association with immune reconstitution disease. AIDS 23 1875 1880
27. WoodR
MiddelkoopK
MyerL
GrantAD
WhitelawA
2007 Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 175 87 93
28. MohammedA
EhrlichR
WoodR
CilliersF
MaartensG
2004 Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 8 792 795
29. ChhengP
TamhaneA
NatpratanC
TanV
LayV
2008 Pulmonary tuberculosis among patients visiting a voluntary confidential counseling and testing center, Cambodia. Int J Tuberc Lung Dis 12 54 62
30. BassettIV
WangB
ChettyS
GiddyJ
LosinaE
2010 Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 51 823 829
31. CrucianiM
ScarparoC
MalenaM
BoscoO
SerpelloniG
2004 Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 42 2321 2325
32. HarbordRM
DeeksJJ
EggerM
WhitingP
SterneJA
2007 A unification of models for meta-analysis of diagnostic accuracy studies. Biostatistics 8 239 251
33. ReitsmaJB
GlasAS
RutjesAW
ScholtenRJ
BossuytPM
2005 Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58 982 990
34. GrimesDA
SchulzKF
2005 Refining clinical diagnosis with likelihood ratios. Lancet 365 1500 1505
35. ReillyB
EvansA
2006 Translating clinical research into clinical practice: impact of using prediction rules to make decisions. An Intern Med 144 210 212
36. WHO 2004 Compendium of indicators for monitoring and evaluating national tuberculosis programs. WHO/HTM/TB/2004.344. Geneva: WHO
37. MosimaneotsileB
TalbotEA
MoetiTL
HoneNM
MoalosiG
2003 Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 362 1551 1552
38. SamandariTAT
ArwadyA
YoonJ
NyirendaS
2007 Asymptomatic pulmonary TB among HIV-infected adults screened for the Botswana isoniazid preventive therapy clinical trial, 2004-2006 [Abstract 862]. In: Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, United States
39. KranzerK
HoubenRM
GlynnJR
BekkerLG
WoodR
2010 Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 10 93 102
40. LawnSD
WoodR
De CockKM
KranzerK
LewisJJ
2010 Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 10 489 498
41. BanerjiD
AndersenS
1963 A sociological study of awareness of symptoms among persons with pulmonary tuberculosis. Bull World Health Organ 29 665 683
42. WHO 2007 Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. WHO/HTM/TB/2007.376 WHO/HIV/2007.01. Geneva: WHO
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2011 Číslo 1
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication
- The Impact of eHealth on the Quality and Safety of Health Care: A Systematic Overview
- Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
- Using the Delphi Technique to Determine Which Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a Systematic Review of Existing Studies